Anette Mertens's articles Biotechnology Angelini Ventures co-leads €20m Series A to advance RNA therapeutics for neurological disorders Copenhagen-based biotech Neumirna Therapeutics has secured €20 million in a Series A funding round co-led by Angelini Ventures and Invivo Partners, with participation from Innovestor’s Life Science Fund and existing investors. The funding will advance Neumirna’s pioneering RNA therapeutics pipeline, including its lead candidate NMT.001, an antisense oligonucleotide (ASO) therapy targeting drug-resistant epilepsy. Founded in […] Written by Anette Mertens January 12, 2025January 12, 2025 Saving Bookmark this article Bookmarked
Biotechnology Angelini Ventures co-leads €20m Series A to advance RNA therapeutics for neurological disorders Copenhagen-based biotech Neumirna Therapeutics has secured €20 million in a Series A funding round co-led by Angelini Ventures and Invivo Partners, with participation from Innovestor’s Life Science Fund and existing investors. The funding will advance Neumirna’s pioneering RNA therapeutics pipeline, including its lead candidate NMT.001, an antisense oligonucleotide (ASO) therapy targeting drug-resistant epilepsy. Founded in […] Written by Anette Mertens January 12, 2025January 12, 2025 Saving Bookmark this article Bookmarked
